These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3376611)

  • 1. [Ototoxic side effects in patients with ovarian cancer treated with cisplatin].
    Behling H; Spieske C; Krafft W
    Zentralbl Gynakol; 1988; 110(5):277-82. PubMed ID: 3376611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ototoxicity of cisplatin in children with malignant diseases].
    Hadjilaskari P; Fengler R; Hartmann R; Henze G
    Klin Padiatr; 1989; 201(4):316-21. PubMed ID: 2779137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ototoxicity of cisplatin chemotherapy in patients with ovarian cancer].
    Beck E; Schuster M; Berg A; Jäger W; Wildt L; Lang N
    Gynakol Rundsch; 1991; 31 Suppl 2():280-5. PubMed ID: 1790954
    [No Abstract]   [Full Text] [Related]  

  • 4. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
    Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
    Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cisplatin ototoxicity. A clinical study].
    Schröder M; Laskawi R; Stennert E; Kühnle H; Thiele FW
    Laryngol Rhinol Otol (Stuttg); 1986 Feb; 65(2):86-9. PubMed ID: 3959692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hearing loss caused by high dose carboplatin therapy].
    Lautermann J; Adamczyk M; ten Cate WJ; Kloke O
    Laryngorhinootologie; 1998 Feb; 77(2):82-4. PubMed ID: 9555700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ototoxicity of cis-diamminedichloroplatinum.
    Vodvárka P; Foukalová J; Mrázek J; Philippová J
    Neoplasma; 1985; 32(2):229-38. PubMed ID: 4039797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experiences with cisplatin (Platidiam) chemotherapy in secondary resistant ovarian carcinomas].
    Krafft W; Mechl Z; Behling H; Brückmann D; Preibsch W; Kademann J; Schirmer A
    Zentralbl Gynakol; 1984; 106(3):175-83. PubMed ID: 6538371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monitoring hearing during ototoxic cisplatin therapy].
    Kluba J; Kluba U; von Specht H; Mittler U
    Padiatr Grenzgeb; 1990; 29(1):19-23. PubMed ID: 2342815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.
    Chan SH; Ng WT; Kam KL; Lee MC; Choi CW; Yau TK; Lee AW; Chow SK
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1335-42. PubMed ID: 18922648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythromycin associated hearing loss in a patient with prior cis-platinum induced ototoxicity.
    Wallach PM; Love SR; Fiorica JV; Hoffman MS; Flannery MT
    J Fla Med Assoc; 1992 Dec; 79(12):821-2. PubMed ID: 1474367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inclusion of cisplatinum (cis-DDP, Platidiam, Lachema) into combined chemotherapeutic protocol for the treatment of testicular cancer.
    Bodrogi I; Baki M; Hindy I; Eckhardt S
    Neoplasma; 1983; 30(5):557-61. PubMed ID: 6197662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-based chemotherapy: Add high-frequency audiometry in the regimen.
    Arora R; Thakur JS; Azad RK; Mohindroo NK; Sharma DR; Seam RK
    Indian J Cancer; 2009; 46(4):311-7. PubMed ID: 19749461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
    Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
    Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
    Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
    Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer].
    Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H
    Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase I study of a combination chemotherapy of nedaplatin and cisplatin].
    Nishida M; Satoh Y; Nishide K; Tsunoda H; Kubo T
    Gan To Kagaku Ryoho; 1999 Dec; 26(14):2209-15. PubMed ID: 10635306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cisplatin treatment: hearing loss and plasma concentrations.
    Laurell G; Jungnelius U
    Laryngoscope; 1990 Jul; 100(7):724-34. PubMed ID: 2362532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased hearing after combined modality therapy for head and neck cancer.
    Pearson SE; Meyer AC; Adams GL; Ondrey FG
    Am J Otolaryngol; 2006; 27(2):76-80. PubMed ID: 16500467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.